Why Mirati Therapeutics Inc. Is Plunging Today

Shares of Mirati Therapeutics (NASDAQ: MRTX), a high-flying biotech focused on cancer, plunged 16% as of 11:35 a.m. on Monday. The drop is a response to the release of clinical data from a phase 2 trial that failed to impress.Mirati presented data from its ongoing phase 2 trial that is testing its compound sitravatinib in combination with Bristol-Myers Squibb's (NYSE: BMY) blockbuster drug Opdivo as a possible treatment for lung cancer.Here's an overview of the key takeaways from the data:Continue reading

Topics:  mirati therapeutics nasdaq   mrtx    squibb's nyse   bmy    data   phase   trial   
BING NEWS:
  • TG Therapeutics Inc. Q1 Loss decreases, but misses estimates
    TG Therapeutics Inc. (TGTX) revealed Loss for first quarter that decreased from last year but missed the Street estimates. The ...
    05/1/2024 - 2:27 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News